ASX ANNOUNCEMENT | 28 JULY 2026

Non-Dilutive Short-Term Funding Secured

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through early and more accurate detection of cancers, advises that it has entered into a loan agreement with its Executive Chairman, Mr. Robert Proulx (**Loan** or **Agreement**). The Loan provides the Company with additional funding under which the Company can draw as and when required to support its working capital requirements.

Key Terms

The principal terms of the loan are as follows:

- Maximum Principal Amount: US$150,000.
- Interest Rate: 8.0% per annum, and only on funds actually drawn.
- Term: Four months from advance of funds under the agreement.
- Security: Unsecured.
- Repayment: Within four months after the date of the any advance of funds.
- Conversion Rights: Subject to certain terms and conditions set out in the Agreement, outstanding amounts advanced under the Agreement (including, where applicable, accrued interest) may be converted into fully paid ordinary shares (**Shares**) in the Company. Any conversion of outstanding loan into Shares will be undertaken in accordance with the terms of the Agreement and the ASX Listing Rules. The conversion is subject to the satisfaction of the relevant conditions and any required shareholder approvals or regulatory approvals.

Commercial Terms

The Board (with the Executive Chairman abstaining from all deliberations and decisions regarding the transaction) considers that the Loan has been entered into on arm’s length commercial terms. The Company believes the financing provides an efficient source of funding and is in the best interests of the Company and all shareholders.

Appendix 3B

In accordance with the ASX Listing Rules, the Company is lodging an Appendix 3B concurrently with this announcement in relation to the potential issue of Shares upon conversion of the loan, should the relevant conditions be satisfied. The Appendix 3B reflects the maximum number of securities that may be issued under the conversion mechanism described in the Agreement.

The Company will make further announcements as appropriate, including if and when any conversion occurs.

Authorisation & Additional Information

This announcement was authorised by the Board of Imagion Biosystems Limited.

Join Imagion Biosystems' Investor Hub

Stay up to date on news and announcements or interact with our team through questions and comments via Investor Hub. Register at investor.imagionbiosystems.com.

About Imagion Biosystems

Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more information, visit imagionbiosystems.com.

Executive Chairman Contact Details
Bob Proulx
investor@imagionbio.com
AU: +61 3 9692 7222

Media Enquiries & Investor Relations
Erich Boileau, Boileau & Co.
imagionbio@boileau.co
US : +1 (616) 786-4461